cancer cell

Recent News

August 2018

aTen Therapeutics has been shortlisted for Corporate LiveWire's Healthcare & Life Sciences Awards 2018, championing the best companies in their respective fields.

May 2018

Francesca Cavallaro joins aTen Therapeutics from the University of Edinburgh to undertake a 3-month work-based MSc project investigating the target of our novel antibody.

Tensinomab product logo

aTen Therapeutics’ lead candidate Tensinomab is a humanised single chain variable fragment (scFv) monoclonal antibody.

Tensinomab selectively modulates the angiotensin II Type 1 receptor (AT1R) which plays a central role in major diseases. In non-clinical testing, we have shown that Tensinomab has potential to treat a broad range of serious medical conditions.

Our lead development programme uses Tensinomab to treat primary cancers and protect against developing metastases, a major cause of cancer death.

In parallel, our development team is researching ATIR modulation to treat other major diseases.

There is mounting evidence demonstrating Tensinomab’s potential to become a significant new therapeutic agent and the aTen Therapeutics team is committed to exploring and exploiting this potential to extend and improve lives.

© aTen Therapeutics 2018. All rights reserved